nodes	percent_of_prediction	percent_of_DWPC	metapath
Icatibant—Goserelin—prostate cancer	0.549	1	CrCtD
Icatibant—Goserelin—Degarelix—prostate cancer	0.14	0.424	CrCrCtD
Icatibant—Gonadorelin—Degarelix—prostate cancer	0.115	0.347	CrCrCtD
Icatibant—Gonadorelin—Goserelin—prostate cancer	0.0759	0.23	CrCrCtD
Icatibant—BDKRB2—penis—prostate cancer	0.0146	0.368	CbGeAlD
Icatibant—BDKRB2—prostate gland—prostate cancer	0.00349	0.0878	CbGeAlD
Icatibant—BDKRB2—seminal vesicle—prostate cancer	0.00295	0.0742	CbGeAlD
Icatibant—BDKRB2—renal system—prostate cancer	0.00238	0.0598	CbGeAlD
Icatibant—BDKRB2—urethra—prostate cancer	0.00234	0.0588	CbGeAlD
Icatibant—ANPEP—prostate gland—prostate cancer	0.00218	0.0547	CbGeAlD
Icatibant—ANPEP—seminal vesicle—prostate cancer	0.00184	0.0463	CbGeAlD
Icatibant—ANPEP—epithelium—prostate cancer	0.0016	0.0402	CbGeAlD
Icatibant—BDKRB2—testis—prostate cancer	0.00154	0.0387	CbGeAlD
Icatibant—ANPEP—renal system—prostate cancer	0.00148	0.0373	CbGeAlD
Icatibant—ANPEP—urethra—prostate cancer	0.00146	0.0366	CbGeAlD
Icatibant—ANPEP—bone marrow—prostate cancer	0.00112	0.0282	CbGeAlD
Icatibant—BDKRB2—lymph node—prostate cancer	0.00111	0.028	CbGeAlD
Icatibant—Injection site reaction—Degarelix—prostate cancer	0.000985	0.0371	CcSEcCtD
Icatibant—ANPEP—testis—prostate cancer	0.000958	0.0241	CbGeAlD
Icatibant—Injection site reaction—Bicalutamide—prostate cancer	0.000796	0.03	CcSEcCtD
Icatibant—ANPEP—lymph node—prostate cancer	0.000695	0.0175	CbGeAlD
Icatibant—Injection site reaction—Goserelin—prostate cancer	0.000554	0.0208	CcSEcCtD
Icatibant—Anaphylactic shock—Estrone—prostate cancer	0.000426	0.016	CcSEcCtD
Icatibant—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.000372	0.014	CcSEcCtD
Icatibant—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.000365	0.0137	CcSEcCtD
Icatibant—Anaphylactic shock—Degarelix—prostate cancer	0.000354	0.0133	CcSEcCtD
Icatibant—Nervous system disorder—Degarelix—prostate cancer	0.000347	0.013	CcSEcCtD
Icatibant—Body temperature increased—Abiraterone—prostate cancer	0.000342	0.0129	CcSEcCtD
Icatibant—Nervous system disorder—Cabazitaxel—prostate cancer	0.000327	0.0123	CcSEcCtD
Icatibant—Body temperature increased—Nilutamide—prostate cancer	0.000313	0.0118	CcSEcCtD
Icatibant—Injection site reaction—Docetaxel—prostate cancer	0.000283	0.0106	CcSEcCtD
Icatibant—Dizziness—Estrone—prostate cancer	0.000282	0.0106	CcSEcCtD
Icatibant—Rash—Estramustine—prostate cancer	0.000281	0.0106	CcSEcCtD
Icatibant—Dermatitis—Estramustine—prostate cancer	0.000281	0.0106	CcSEcCtD
Icatibant—Nervous system disorder—Bicalutamide—prostate cancer	0.00028	0.0105	CcSEcCtD
Icatibant—Body temperature increased—Degarelix—prostate cancer	0.000279	0.0105	CcSEcCtD
Icatibant—Headache—Estramustine—prostate cancer	0.000279	0.0105	CcSEcCtD
Icatibant—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000274	0.0103	CcSEcCtD
Icatibant—Injection site reaction—Capecitabine—prostate cancer	0.000274	0.0103	CcSEcCtD
Icatibant—Rash—Abiraterone—prostate cancer	0.000273	0.0103	CcSEcCtD
Icatibant—Dermatitis—Abiraterone—prostate cancer	0.000273	0.0103	CcSEcCtD
Icatibant—Rash—Estrone—prostate cancer	0.000269	0.0101	CcSEcCtD
Icatibant—Dermatitis—Estrone—prostate cancer	0.000268	0.0101	CcSEcCtD
Icatibant—Headache—Estrone—prostate cancer	0.000267	0.01	CcSEcCtD
Icatibant—Nausea—Estramustine—prostate cancer	0.000265	0.00997	CcSEcCtD
Icatibant—Body temperature increased—Cabazitaxel—prostate cancer	0.000263	0.00991	CcSEcCtD
Icatibant—Dizziness—Nilutamide—prostate cancer	0.000262	0.00985	CcSEcCtD
Icatibant—Dizziness—Flutamide—prostate cancer	0.000261	0.0098	CcSEcCtD
Icatibant—Hypersensitivity—Degarelix—prostate cancer	0.00026	0.0098	CcSEcCtD
Icatibant—Nausea—Estrone—prostate cancer	0.000253	0.00952	CcSEcCtD
Icatibant—Rash—Nilutamide—prostate cancer	0.00025	0.00939	CcSEcCtD
Icatibant—Dermatitis—Nilutamide—prostate cancer	0.000249	0.00938	CcSEcCtD
Icatibant—Rash—Flutamide—prostate cancer	0.000248	0.00935	CcSEcCtD
Icatibant—Dermatitis—Flutamide—prostate cancer	0.000248	0.00934	CcSEcCtD
Icatibant—Headache—Nilutamide—prostate cancer	0.000248	0.00933	CcSEcCtD
Icatibant—Headache—Flutamide—prostate cancer	0.000247	0.00929	CcSEcCtD
Icatibant—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000246	0.00925	CcSEcCtD
Icatibant—Hypersensitivity—Cabazitaxel—prostate cancer	0.000245	0.00923	CcSEcCtD
Icatibant—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.000237	0.00891	CcSEcCtD
Icatibant—Nausea—Nilutamide—prostate cancer	0.000235	0.00884	CcSEcCtD
Icatibant—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000234	0.00882	CcSEcCtD
Icatibant—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000234	0.00881	CcSEcCtD
Icatibant—Nausea—Flutamide—prostate cancer	0.000234	0.00881	CcSEcCtD
Icatibant—Dizziness—Degarelix—prostate cancer	0.000234	0.0088	CcSEcCtD
Icatibant—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000233	0.00876	CcSEcCtD
Icatibant—Body temperature increased—Bicalutamide—prostate cancer	0.000226	0.0085	CcSEcCtD
Icatibant—Rash—Degarelix—prostate cancer	0.000223	0.00839	CcSEcCtD
Icatibant—Dermatitis—Degarelix—prostate cancer	0.000223	0.00838	CcSEcCtD
Icatibant—Headache—Degarelix—prostate cancer	0.000221	0.00833	CcSEcCtD
Icatibant—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000221	0.00831	CcSEcCtD
Icatibant—Dizziness—Cabazitaxel—prostate cancer	0.00022	0.00829	CcSEcCtD
Icatibant—Hypersensitivity—Bicalutamide—prostate cancer	0.00021	0.00792	CcSEcCtD
Icatibant—Nausea—Degarelix—prostate cancer	0.00021	0.0079	CcSEcCtD
Icatibant—Headache—Cabazitaxel—prostate cancer	0.000209	0.00785	CcSEcCtD
Icatibant—Anaphylactic shock—Goserelin—prostate cancer	0.000199	0.00748	CcSEcCtD
Icatibant—Nausea—Cabazitaxel—prostate cancer	0.000198	0.00744	CcSEcCtD
Icatibant—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000197	0.00741	CcSEcCtD
Icatibant—Nervous system disorder—Goserelin—prostate cancer	0.000195	0.00733	CcSEcCtD
Icatibant—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000193	0.00726	CcSEcCtD
Icatibant—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.000191	0.00718	CcSEcCtD
Icatibant—Injection site reaction—Epirubicin—prostate cancer	0.000191	0.00718	CcSEcCtD
Icatibant—Dizziness—Bicalutamide—prostate cancer	0.000189	0.00711	CcSEcCtD
Icatibant—Rash—Bicalutamide—prostate cancer	0.00018	0.00678	CcSEcCtD
Icatibant—Dermatitis—Bicalutamide—prostate cancer	0.00018	0.00677	CcSEcCtD
Icatibant—Headache—Bicalutamide—prostate cancer	0.000179	0.00673	CcSEcCtD
Icatibant—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000178	0.00669	CcSEcCtD
Icatibant—Injection site reaction—Doxorubicin—prostate cancer	0.000176	0.00664	CcSEcCtD
Icatibant—Nausea—Bicalutamide—prostate cancer	0.00017	0.00639	CcSEcCtD
Icatibant—Dizziness—Ethinyl Estradiol—prostate cancer	0.00016	0.00601	CcSEcCtD
Icatibant—Anaphylactic shock—Estradiol—prostate cancer	0.000158	0.00593	CcSEcCtD
Icatibant—Body temperature increased—Goserelin—prostate cancer	0.000157	0.00591	CcSEcCtD
Icatibant—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000156	0.00586	CcSEcCtD
Icatibant—Nervous system disorder—Estradiol—prostate cancer	0.000155	0.00581	CcSEcCtD
Icatibant—Rash—Ethinyl Estradiol—prostate cancer	0.000152	0.00573	CcSEcCtD
Icatibant—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000152	0.00572	CcSEcCtD
Icatibant—Headache—Ethinyl Estradiol—prostate cancer	0.000151	0.00569	CcSEcCtD
Icatibant—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000147	0.00552	CcSEcCtD
Icatibant—Hypersensitivity—Goserelin—prostate cancer	0.000146	0.00551	CcSEcCtD
Icatibant—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000145	0.00546	CcSEcCtD
Icatibant—Nausea—Ethinyl Estradiol—prostate cancer	0.000143	0.0054	CcSEcCtD
Icatibant—Dizziness—Goserelin—prostate cancer	0.000131	0.00494	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—PTGS2—prostate cancer	0.00013	0.00241	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PDGFRB—prostate cancer	0.00013	0.00241	CbGpPWpGaD
Icatibant—Dizziness—Conjugated Estrogens—prostate cancer	0.00013	0.0049	CcSEcCtD
Icatibant—Rash—Goserelin—prostate cancer	0.000125	0.00471	CcSEcCtD
Icatibant—Dermatitis—Goserelin—prostate cancer	0.000125	0.00471	CcSEcCtD
Icatibant—Body temperature increased—Estradiol—prostate cancer	0.000125	0.00469	CcSEcCtD
Icatibant—Headache—Goserelin—prostate cancer	0.000125	0.00468	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—MUC4—prostate cancer	0.000124	0.0023	CbGpPWpGaD
Icatibant—Rash—Conjugated Estrogens—prostate cancer	0.000124	0.00467	CcSEcCtD
Icatibant—Dermatitis—Conjugated Estrogens—prostate cancer	0.000124	0.00467	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—CDKN1B—prostate cancer	0.000124	0.00229	CbGpPWpGaD
Icatibant—Headache—Conjugated Estrogens—prostate cancer	0.000123	0.00464	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—FGFR2—prostate cancer	0.000123	0.00227	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (i) signalling events—CXCL12—prostate cancer	0.000123	0.00227	CbGpPWpGaD
Icatibant—Anaphylactic shock—Etoposide—prostate cancer	0.000122	0.00459	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	0.00012	0.00222	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—RGS17—prostate cancer	0.00012	0.00222	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (q) signalling events—ITPR1—prostate cancer	0.00012	0.00221	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—BCL2L1—prostate cancer	0.000119	0.0022	CbGpPWpGaD
Icatibant—Nausea—Goserelin—prostate cancer	0.000118	0.00444	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—CCND1—prostate cancer	0.000118	0.00218	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—RLN2—prostate cancer	0.000118	0.00218	CbGpPWpGaD
Icatibant—Nausea—Conjugated Estrogens—prostate cancer	0.000117	0.0044	CcSEcCtD
Icatibant—Hypersensitivity—Estradiol—prostate cancer	0.000116	0.00437	CcSEcCtD
Icatibant—Body temperature increased—Mitoxantrone—prostate cancer	0.000116	0.00437	CcSEcCtD
Icatibant—ANPEP—Peptide hormone metabolism—CTNNB1—prostate cancer	0.000116	0.00214	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—CAV1—prostate cancer	0.000115	0.00212	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—CDKN1A—prostate cancer	0.000114	0.00211	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—GNRH1—prostate cancer	0.000114	0.00211	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—LPAR1—prostate cancer	0.00011	0.00204	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—GRP—prostate cancer	0.00011	0.00204	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—RPL12—prostate cancer	0.000109	0.00201	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—EP300—prostate cancer	0.000109	0.00201	CbGpPWpGaD
Icatibant—Hypersensitivity—Mitoxantrone—prostate cancer	0.000108	0.00407	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—PLXNB1—prostate cancer	0.000108	0.00199	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—CX3CL1—prostate cancer	0.000107	0.00198	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	0.000107	0.00198	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—RLN2—prostate cancer	0.000107	0.00198	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000107	0.00197	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—APC—prostate cancer	0.000104	0.00193	CbGpPWpGaD
Icatibant—Dizziness—Estradiol—prostate cancer	0.000104	0.00392	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—GRPR—prostate cancer	0.000103	0.00191	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—HSP90B1—prostate cancer	0.000103	0.00191	CbGpPWpGaD
Icatibant—Anaphylactic shock—Docetaxel—prostate cancer	0.000101	0.00382	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—EIF3A—prostate cancer	9.98e-05	0.00185	CbGpPWpGaD
Icatibant—Nervous system disorder—Docetaxel—prostate cancer	9.95e-05	0.00374	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CG—prostate cancer	9.94e-05	0.00184	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—APC—prostate cancer	9.94e-05	0.00184	CbGpPWpGaD
Icatibant—Rash—Estradiol—prostate cancer	9.93e-05	0.00374	CcSEcCtD
Icatibant—Dermatitis—Estradiol—prostate cancer	9.92e-05	0.00373	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—GNG5—prostate cancer	9.91e-05	0.00183	CbGpPWpGaD
Icatibant—Headache—Estradiol—prostate cancer	9.87e-05	0.00371	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—EGF—prostate cancer	9.82e-05	0.00182	CbGpPWpGaD
Icatibant—BDKRB2—GPCRs, Class A Rhodopsin-like—ADRB2—prostate cancer	9.77e-05	0.00181	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PLXNB1—prostate cancer	9.76e-05	0.00181	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	9.75e-05	0.0018	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—CREBBP—prostate cancer	9.69e-05	0.00179	CbGpPWpGaD
Icatibant—Body temperature increased—Etoposide—prostate cancer	9.65e-05	0.00363	CcSEcCtD
Icatibant—Nervous system disorder—Capecitabine—prostate cancer	9.64e-05	0.00363	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—MYC—prostate cancer	9.46e-05	0.00175	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—GRPR—prostate cancer	9.4e-05	0.00174	CbGpPWpGaD
Icatibant—Nausea—Estradiol—prostate cancer	9.36e-05	0.00352	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—MMP2—prostate cancer	9.26e-05	0.00171	CbGpPWpGaD
Icatibant—Rash—Mitoxantrone—prostate cancer	9.26e-05	0.00348	CcSEcCtD
Icatibant—Dermatitis—Mitoxantrone—prostate cancer	9.25e-05	0.00348	CcSEcCtD
Icatibant—Headache—Mitoxantrone—prostate cancer	9.2e-05	0.00346	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—SERPINE1—prostate cancer	9.08e-05	0.00168	CbGpPWpGaD
Icatibant—Hypersensitivity—Etoposide—prostate cancer	9e-05	0.00338	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—MME—prostate cancer	8.86e-05	0.00164	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—MAP2K1—prostate cancer	8.79e-05	0.00163	CbGpPWpGaD
Icatibant—Anaphylactic shock—Prednisone—prostate cancer	8.75e-05	0.00329	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—KRAS—prostate cancer	8.74e-05	0.00162	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CD—prostate cancer	8.74e-05	0.00162	CbGpPWpGaD
Icatibant—Nausea—Mitoxantrone—prostate cancer	8.72e-05	0.00328	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—PTHLH—prostate cancer	8.64e-05	0.0016	CbGpPWpGaD
Icatibant—Nervous system disorder—Prednisone—prostate cancer	8.58e-05	0.00323	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—MC2R—prostate cancer	8.5e-05	0.00157	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—GRP—prostate cancer	8.49e-05	0.00157	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	8.37e-05	0.00155	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—FGF2—prostate cancer	8.37e-05	0.00155	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—BCL2—prostate cancer	8.35e-05	0.00155	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—OR51E2—prostate cancer	8.32e-05	0.00154	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—RPL10—prostate cancer	8.24e-05	0.00152	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—MDM2—prostate cancer	8.23e-05	0.00152	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—ANXA1—prostate cancer	8.12e-05	0.0015	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—WNT4—prostate cancer	8.09e-05	0.0015	CbGpPWpGaD
Icatibant—Dizziness—Etoposide—prostate cancer	8.07e-05	0.00304	CcSEcCtD
Icatibant—Body temperature increased—Docetaxel—prostate cancer	8.02e-05	0.00302	CcSEcCtD
Icatibant—Body temperature increased—Capecitabine—prostate cancer	7.77e-05	0.00292	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—MC2R—prostate cancer	7.72e-05	0.00143	CbGpPWpGaD
Icatibant—Rash—Etoposide—prostate cancer	7.7e-05	0.0029	CcSEcCtD
Icatibant—Dermatitis—Etoposide—prostate cancer	7.69e-05	0.00289	CcSEcCtD
Icatibant—Headache—Etoposide—prostate cancer	7.65e-05	0.00288	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CB—prostate cancer	7.62e-05	0.00141	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—BMPR1B—prostate cancer	7.61e-05	0.00141	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—CALCA—prostate cancer	7.6e-05	0.00141	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PENK—prostate cancer	7.57e-05	0.0014	CbGpPWpGaD
Icatibant—Hypersensitivity—Docetaxel—prostate cancer	7.48e-05	0.00281	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—CXCL12—prostate cancer	7.43e-05	0.00137	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—ATF3—prostate cancer	7.4e-05	0.00137	CbGpPWpGaD
Icatibant—Nausea—Etoposide—prostate cancer	7.25e-05	0.00273	CcSEcCtD
Icatibant—Hypersensitivity—Capecitabine—prostate cancer	7.24e-05	0.00272	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—RGS17—prostate cancer	7.07e-05	0.00131	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—IGFBP3—prostate cancer	6.96e-05	0.00129	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—CDKN1A—prostate cancer	6.93e-05	0.00128	CbGpPWpGaD
Icatibant—Body temperature increased—Prednisone—prostate cancer	6.92e-05	0.0026	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—PTEN—prostate cancer	6.92e-05	0.00128	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PENK—prostate cancer	6.88e-05	0.00127	CbGpPWpGaD
Icatibant—Anaphylactic shock—Epirubicin—prostate cancer	6.84e-05	0.00258	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—ACHE—prostate cancer	6.8e-05	0.00126	CbGpPWpGaD
Icatibant—Nervous system disorder—Epirubicin—prostate cancer	6.71e-05	0.00253	CcSEcCtD
Icatibant—Dizziness—Docetaxel—prostate cancer	6.71e-05	0.00252	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—EP300—prostate cancer	6.6e-05	0.00122	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	6.56e-05	0.00121	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—RPS19—prostate cancer	6.53e-05	0.00121	CbGpPWpGaD
Icatibant—Dizziness—Capecitabine—prostate cancer	6.5e-05	0.00244	CcSEcCtD
Icatibant—Hypersensitivity—Prednisone—prostate cancer	6.45e-05	0.00243	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—VIP—prostate cancer	6.44e-05	0.00119	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—GNRH1—prostate cancer	6.44e-05	0.00119	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—CTSD—prostate cancer	6.43e-05	0.00119	CbGpPWpGaD
Icatibant—Rash—Docetaxel—prostate cancer	6.4e-05	0.00241	CcSEcCtD
Icatibant—Dermatitis—Docetaxel—prostate cancer	6.39e-05	0.00241	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—ADRB2—prostate cancer	6.37e-05	0.00118	CbGpPWpGaD
Icatibant—Headache—Docetaxel—prostate cancer	6.36e-05	0.00239	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—THBS1—prostate cancer	6.34e-05	0.00117	CbGpPWpGaD
Icatibant—Anaphylactic shock—Doxorubicin—prostate cancer	6.33e-05	0.00238	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—RLN2—prostate cancer	6.31e-05	0.00117	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—GRP—prostate cancer	6.24e-05	0.00115	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—LPAR1—prostate cancer	6.24e-05	0.00115	CbGpPWpGaD
Icatibant—Nervous system disorder—Doxorubicin—prostate cancer	6.21e-05	0.00234	CcSEcCtD
Icatibant—Rash—Capecitabine—prostate cancer	6.19e-05	0.00233	CcSEcCtD
Icatibant—Dermatitis—Capecitabine—prostate cancer	6.19e-05	0.00233	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—PLCB2—prostate cancer	6.17e-05	0.00114	CbGpPWpGaD
Icatibant—Headache—Capecitabine—prostate cancer	6.16e-05	0.00232	CcSEcCtD
Icatibant—Nausea—Docetaxel—prostate cancer	6.03e-05	0.00227	CcSEcCtD
Icatibant—BDKRB2—Peptide ligand-binding receptors—CXCL8—prostate cancer	6.02e-05	0.00111	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—CALR—prostate cancer	6.02e-05	0.00111	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HSD17B1—prostate cancer	6.02e-05	0.00111	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CTBP2—prostate cancer	6.02e-05	0.00111	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	5.98e-05	0.00111	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PDE4D—prostate cancer	5.89e-05	0.00109	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—GNRH1—prostate cancer	5.85e-05	0.00108	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—VIP—prostate cancer	5.85e-05	0.00108	CbGpPWpGaD
Icatibant—Nausea—Capecitabine—prostate cancer	5.84e-05	0.0022	CcSEcCtD
Icatibant—Dizziness—Prednisone—prostate cancer	5.79e-05	0.00218	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—PLXNB1—prostate cancer	5.77e-05	0.00107	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—ACE—prostate cancer	5.73e-05	0.00106	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—GRP—prostate cancer	5.66e-05	0.00105	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—LPAR1—prostate cancer	5.66e-05	0.00105	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—EGFR—prostate cancer	5.62e-05	0.00104	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PLCB2—prostate cancer	5.61e-05	0.00104	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—GNG5—prostate cancer	5.6e-05	0.00104	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GRPR—prostate cancer	5.55e-05	0.00103	CbGpPWpGaD
Icatibant—Rash—Prednisone—prostate cancer	5.52e-05	0.00208	CcSEcCtD
Icatibant—Dermatitis—Prednisone—prostate cancer	5.51e-05	0.00207	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CX3CL1—prostate cancer	5.5e-05	0.00102	CbGpPWpGaD
Icatibant—Headache—Prednisone—prostate cancer	5.48e-05	0.00206	CcSEcCtD
Icatibant—Body temperature increased—Epirubicin—prostate cancer	5.41e-05	0.00204	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—IL17RD—prostate cancer	5.36e-05	0.000992	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PDE4D—prostate cancer	5.35e-05	0.00099	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—EGFR—prostate cancer	5.35e-05	0.00099	CbGpPWpGaD
Icatibant—Nausea—Prednisone—prostate cancer	5.2e-05	0.00196	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—PLAUR—prostate cancer	5.15e-05	0.000953	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—GNG5—prostate cancer	5.09e-05	0.000941	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (i) signalling events—CXCL8—prostate cancer	5.08e-05	0.000941	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—KRAS—prostate cancer	5.05e-05	0.000935	CbGpPWpGaD
Icatibant—Hypersensitivity—Epirubicin—prostate cancer	5.04e-05	0.0019	CcSEcCtD
Icatibant—Body temperature increased—Doxorubicin—prostate cancer	5.01e-05	0.00188	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—PTHLH—prostate cancer	4.88e-05	0.000903	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—JUP—prostate cancer	4.78e-05	0.000884	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—WNT4—prostate cancer	4.78e-05	0.000884	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—TP53—prostate cancer	4.72e-05	0.000874	CbGpPWpGaD
Icatibant—Hypersensitivity—Doxorubicin—prostate cancer	4.67e-05	0.00176	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CA—prostate cancer	4.64e-05	0.000859	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—ANXA1—prostate cancer	4.59e-05	0.000849	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—RALBP1—prostate cancer	4.56e-05	0.000844	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MC2R—prostate cancer	4.56e-05	0.000844	CbGpPWpGaD
Icatibant—Dizziness—Epirubicin—prostate cancer	4.53e-05	0.0017	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PTHLH—prostate cancer	4.43e-05	0.00082	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PRKACB—prostate cancer	4.34e-05	0.000803	CbGpPWpGaD
Icatibant—Rash—Epirubicin—prostate cancer	4.32e-05	0.00162	CcSEcCtD
Icatibant—Dermatitis—Epirubicin—prostate cancer	4.31e-05	0.00162	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—CALCA—prostate cancer	4.3e-05	0.000795	CbGpPWpGaD
Icatibant—Headache—Epirubicin—prostate cancer	4.29e-05	0.00161	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PPP3CA—prostate cancer	4.23e-05	0.000782	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—CXCL12—prostate cancer	4.2e-05	0.000777	CbGpPWpGaD
Icatibant—Dizziness—Doxorubicin—prostate cancer	4.19e-05	0.00158	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—ANXA1—prostate cancer	4.17e-05	0.000771	CbGpPWpGaD
Icatibant—Nausea—Epirubicin—prostate cancer	4.07e-05	0.00153	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—PENK—prostate cancer	4.06e-05	0.000752	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	4.04e-05	0.000748	CbGpPWpGaD
Icatibant—Rash—Doxorubicin—prostate cancer	3.99e-05	0.0015	CcSEcCtD
Icatibant—Dermatitis—Doxorubicin—prostate cancer	3.99e-05	0.0015	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	3.99e-05	0.000738	CbGpPWpGaD
Icatibant—Headache—Doxorubicin—prostate cancer	3.97e-05	0.00149	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CALCA—prostate cancer	3.9e-05	0.000722	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GHR—prostate cancer	3.88e-05	0.000717	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (q) signalling events—PIK3CA—prostate cancer	3.87e-05	0.000716	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PRKCQ—prostate cancer	3.83e-05	0.000709	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CXCL12—prostate cancer	3.81e-05	0.000705	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	3.77e-05	0.000697	CbGpPWpGaD
Icatibant—Nausea—Doxorubicin—prostate cancer	3.76e-05	0.00142	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—NRP1—prostate cancer	3.72e-05	0.000688	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—ADRB2—prostate cancer	3.6e-05	0.000666	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—LEP—prostate cancer	3.56e-05	0.000659	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—VAV3—prostate cancer	3.51e-05	0.00065	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PRKCQ—prostate cancer	3.48e-05	0.000644	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	3.46e-05	0.000641	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—VIP—prostate cancer	3.45e-05	0.000639	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GNRH1—prostate cancer	3.45e-05	0.000639	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—ITPR1—prostate cancer	3.41e-05	0.00063	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GRP—prostate cancer	3.35e-05	0.000619	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LPAR1—prostate cancer	3.35e-05	0.000619	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PLCB2—prostate cancer	3.31e-05	0.000613	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LRP2—prostate cancer	3.31e-05	0.000613	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—ADRB2—prostate cancer	3.27e-05	0.000605	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—P4HB—prostate cancer	3.25e-05	0.000601	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CX3CL1—prostate cancer	3.25e-05	0.000601	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—VAV3—prostate cancer	3.19e-05	0.00059	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HIST1H2BG—prostate cancer	3.19e-05	0.00059	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDE4D—prostate cancer	3.16e-05	0.000585	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GRB7—prostate cancer	3.16e-05	0.000585	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—ITPR1—prostate cancer	3.09e-05	0.000572	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HIST1H4H—prostate cancer	3.08e-05	0.00057	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—CXCL8—prostate cancer	3.08e-05	0.000569	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	3.07e-05	0.000567	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—INS—prostate cancer	3.04e-05	0.000563	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GNG5—prostate cancer	3.01e-05	0.000556	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—IGF1—prostate cancer	2.94e-05	0.000545	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—MMP2—prostate cancer	2.85e-05	0.000527	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTHLH—prostate cancer	2.62e-05	0.000485	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TGFBR1—prostate cancer	2.62e-05	0.000485	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—AKR1C3—prostate cancer	2.58e-05	0.000477	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PRKACB—prostate cancer	2.56e-05	0.000474	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—THBS1—prostate cancer	2.5e-05	0.000462	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PPP3CA—prostate cancer	2.5e-05	0.000462	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ANXA1—prostate cancer	2.46e-05	0.000456	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PRKCZ—prostate cancer	2.42e-05	0.000447	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—CXCL8—prostate cancer	2.37e-05	0.000438	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CG—prostate cancer	2.36e-05	0.000437	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGFR4—prostate cancer	2.33e-05	0.000432	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PARP1—prostate cancer	2.33e-05	0.000432	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CALCA—prostate cancer	2.31e-05	0.000427	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CXCL12—prostate cancer	2.25e-05	0.000417	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—CTNNB1—prostate cancer	2.18e-05	0.000404	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CG—prostate cancer	2.14e-05	0.000397	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CASP9—prostate cancer	2.12e-05	0.000392	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CD—prostate cancer	2.08e-05	0.000384	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PRKCQ—prostate cancer	2.05e-05	0.00038	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NGFR—prostate cancer	2.05e-05	0.00038	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAP3K7—prostate cancer	2.03e-05	0.000376	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGF10—prostate cancer	1.95e-05	0.000361	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ADRB2—prostate cancer	1.93e-05	0.000357	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—JAK2—prostate cancer	1.91e-05	0.000353	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—MAP2K1—prostate cancer	1.9e-05	0.000351	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CD—prostate cancer	1.89e-05	0.000349	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—VAV3—prostate cancer	1.88e-05	0.000349	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TGFBR2—prostate cancer	1.86e-05	0.000344	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ITPR1—prostate cancer	1.83e-05	0.000338	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.81e-05	0.000335	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IGF1R—prostate cancer	1.75e-05	0.000323	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—CXCL8—prostate cancer	1.74e-05	0.000322	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—JAK2—prostate cancer	1.73e-05	0.00032	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LPL—prostate cancer	1.67e-05	0.00031	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—IL2—prostate cancer	1.66e-05	0.000308	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDGFRB—prostate cancer	1.66e-05	0.000307	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CB—prostate cancer	1.64e-05	0.000304	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ITGB3—prostate cancer	1.62e-05	0.000299	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CXCL8—prostate cancer	1.58e-05	0.000292	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ERBB3—prostate cancer	1.57e-05	0.00029	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGFR2—prostate cancer	1.57e-05	0.00029	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL2—prostate cancer	1.51e-05	0.000279	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TERT—prostate cancer	1.5e-05	0.000278	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HIF1A—prostate cancer	1.44e-05	0.000266	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LEP—prostate cancer	1.4e-05	0.00026	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CAV1—prostate cancer	1.39e-05	0.000257	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—KDR—prostate cancer	1.38e-05	0.000255	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ESR1—prostate cancer	1.34e-05	0.000248	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—BAD—prostate cancer	1.31e-05	0.000242	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—APC—prostate cancer	1.27e-05	0.000234	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CG—prostate cancer	1.27e-05	0.000234	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EGF—prostate cancer	1.25e-05	0.000232	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IRS1—prostate cancer	1.25e-05	0.000232	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GSK3B—prostate cancer	1.22e-05	0.000225	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—INS—prostate cancer	1.2e-05	0.000222	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CREBBP—prostate cancer	1.17e-05	0.000217	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IGF1—prostate cancer	1.16e-05	0.000215	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—EGFR—prostate cancer	1.15e-05	0.000214	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAP2K1—prostate cancer	1.12e-05	0.000207	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CD—prostate cancer	1.11e-05	0.000206	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CA—prostate cancer	1.1e-05	0.000204	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SERPINE1—prostate cancer	1.1e-05	0.000204	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—KRAS—prostate cancer	1.09e-05	0.000202	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGF2—prostate cancer	1.07e-05	0.000197	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NOS3—prostate cancer	1.05e-05	0.000195	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—JAK2—prostate cancer	1.02e-05	0.000189	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CA—prostate cancer	1e-05	0.000185	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MDM2—prostate cancer	9.98e-06	0.000185	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ERBB2—prostate cancer	9.84e-06	0.000182	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CB—prostate cancer	9.71e-06	0.00018	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CXCL8—prostate cancer	9.33e-06	0.000173	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CDKN1B—prostate cancer	9.11e-06	0.000169	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—AKT1—prostate cancer	9.01e-06	0.000167	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CASP3—prostate cancer	8.93e-06	0.000165	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL2—prostate cancer	8.92e-06	0.000165	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL6—prostate cancer	8.87e-06	0.000164	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCND1—prostate cancer	8.69e-06	0.000161	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CTNNB1—prostate cancer	8.61e-06	0.000159	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MMP9—prostate cancer	8.44e-06	0.000156	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CDKN1A—prostate cancer	8.41e-06	0.000156	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTEN—prostate cancer	8.39e-06	0.000155	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—AKT1—prostate cancer	8.18e-06	0.000151	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EP300—prostate cancer	8e-06	0.000148	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SRC—prostate cancer	7.78e-06	0.000144	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—VEGFA—prostate cancer	7.58e-06	0.00014	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—STAT3—prostate cancer	7.5e-06	0.000139	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MYC—prostate cancer	6.97e-06	0.000129	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TGFB1—prostate cancer	6.95e-06	0.000129	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EGFR—prostate cancer	6.82e-06	0.000126	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—KRAS—prostate cancer	6.44e-06	0.000119	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CA—prostate cancer	5.92e-06	0.00011	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TP53—prostate cancer	5.73e-06	0.000106	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL6—prostate cancer	5.24e-06	9.7e-05	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—AKT1—prostate cancer	4.83e-06	8.95e-05	CbGpPWpGaD
